Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics_resized
IRLAB (OMX: IRLAB-A) receives EMA waiver for mesdopetam paediatric studies
Published by Arron Aatkar, PhD

IRLAB has announced that it has received a waiver from the European Medicines Agency, which means it does not have to perform studies of its lead asset, mesdopetam, in children. This would otherwise have been mandatory to support a European marketing authorisation application. Consequently, IRLAB can now focus its efforts in patient groups where Parkinson’s disease (PD) is more prevalent, such as in older populations, and hence avoid resource-demanding and lengthy studies in the paediatric population.

Mesdopetam is IRLAB’s lead clinical candidate, which is being developed as a potential treatment for levodopa-induced dyskinesias in PD patients. The company is currently preparing for Phase III.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.